Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Ltd

Mr. Geoffrey Paul Kempler B.Sc.

Co-Founder & Non-Executive Chairman

Dr. David A. Stamler M.D.

Chief Executive Officer

Ms. Abby  Macnish Niven B.Com., B.Sc., C.F.A.

CFO & Company Secretary

Dr. Rudolph Emile Tanzi Ph.D.

Chief Scientific Advisor and Member of Research & Development Advisory Board

Dr. Steven D. Targum M.D.

Chief Medical Advisor

Dr. Robert  Cherny

Head of Research

Alterity Therapeutics Ltd (ATH) Stock Analysis, Discussion Forum and Financial Metrics - ASX Exchange

ATH Stock Discussion Forum and Message Board

News for ASX: ATH